Sepsis Diagnostics Market

Sepsis Diagnostics Market by Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User - Global Forecast to 2023

Report Code: MD 4575 Oct, 2019, by marketsandmarkets.com

[193 Pages Report] The global sepsis diagnostics market was valued at USD 367.9 Million in 2017 and is expected to reach USD 613.9 Million by 2023, at a CAGR of 9.1% during the forecast period.

  • Base Year: 2017
  • Forecast Period: 2018–2023

Market Dynamics

High incidence of sepsis in the adult population

The prevalence of sepsis has increased significantly over the last decade, and the condition is responsible for more number of deaths than other disease conditions, such as bowel and breast cancer combined. The major factors responsible for the significant growth in the prevalence of sepsis include the rising geriatric population, development of drug-resistance among individuals, and rise in virulent varieties of infections. According to the Global Sepsis Alliance, every year, approximately 26 million people develop sepsis globally, and around 8 million people die of sepsis each year. In the US, more than 1.6 million people are diagnosed with sepsis every year, and the incidence rate is expected to grow by 8% each year. According to the Global Sepsis Alliance, in the US, sepsis accounts for far more number of deaths than prostate cancer, breast cancer, and AIDS combined. Likewise, sepsis is the third major cause of death among people in Germany. In line with this, according to a study conducted in Germany, from 2007–2013, the incidence of sepsis increased by a mean of 15% per year to reach 252,812 cases from 110,653.

Lack of established reimbursement policies for sepsis

In various countries, the reimbursement structure for a broad range of diagnostic tests is often unfavorable. In the US and Germany, authorities reimburse hospitals for the entire cost of disease treatment, so that if a patient stays in a hospital longer than the anticipated time, the hospital has to bear the additional cost. The presence of such a structure discourages the use of diagnostic tools, including sepsis tests, if extra testing is expected as it can potentially result in reduced profits or financial losses per patient.

In Japan, for the reimbursement of any medical condition, healthcare providers are required to submit health insurance claims (HICs) to the Health Insurance Claims Review & Reimbursement Services (HICRRS) or to the National Health Insurance Organization (NHIO), which determines a patient’s eligibility for coverage under the existing reimbursement policies. Disease-specific medical expenditure in Japan is classified in broad disease categories based on the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). The medical expenditure for sepsis is not yet established in Japan as sepsis is classified under the broad category of “other infectious diseases and parasitic diseases.”

Similarly, there are no established reimbursement policies for the diagnosis and treatment of sepsis in emerging and less-developed countries. Thus, the unfavorable reimbursement scenario for diagnostic devices is expected to negatively affect the growth of the market during the forecast period.

Evolution of novel biomarkers for sepsis diagnosis

Biomarkers for the diagnosis of sepsis enable early diagnosis and reduce the risk of mortality among patients. Lactate is the most commonly used biomarker for the identification of sepsis. Other biomarkers are used for enhancing the effect of lactate and help in sepsis identification. There are ~178 different sepsis biomarkers described in medical literature based on the complexity of sepsis pathophysiology. Out of these, Procalcitonin holds significant importance in the detection of bloodstream infections.

Procalcitonin test (PCT) has evolved as a promising biomarker that reacts with high sensitivity and specificity to generalized infections and sepsis. This test is used for evaluating risks in a critically ill patient who is developing a severe systemic bacterial infection. Procalcitonin as a sepsis biomarker provides greater specificity as compared to other proinflammatory markers, such as leukocyte cell count, C reactive protein (CRP), and cytokines (TNF-α, IL-1β, or IL-6). In addition, it provides specific differentiation between a severe bacterial infection and other inflammatory reactions. Owing to its specificity to bacterial infections, PCT has emerged as a pertinent marker in the rapid diagnosis of sepsis, especially for use in hospital emergency departments and ICUs. Thus, PCT test helps in addressing the current clinical challenges (low specificity and slow turnaround time) associated with conventional lab tests and has become one of the most important components of sepsis diagnosis protocols across Europe and the US to provide relevant information for clinical decision making. Thus, companies are increasingly focusing on the development of PCT assays for sepsis diagnosis

Shortage of skilled healthcare professionals

Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals, including lab technicians, paramedics, intensivists, doctors, and nurses. The shortage of skilled professionals is a major concern worldwide; only 50% of the patients with severe sepsis transported by the EMS system have a paramedic. Lack of trained paramedics has an effect during each phase of patient care—sepsis awareness, screening patients for the presence of sepsis, and making an appropriate decision after diagnosis.

Objectives of the study are

  • To define, describe, and forecast the global market by technology, product, test type, pathogen, method, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide a five-year forecast for various segments of the market in terms of revenue with respect to the four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as product launches, agreements, partnerships, collaborations, and product approvals in the global market

This research study involved the extensive usage of secondary sources, directories, and databases (such as D&B and Factiva), to identify and collect information useful for this technical, market-oriented, and financial study of the market. In-depth interviews were conducted with various primary respondents, including subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify qualitative and quantitative information and to assess market prospects.

Sepsis Diagnostics Market - Breakup of Primary Interviews

To get more details on this report, Download PDF Brochure

As of 2016, the global sepsis diagnostics industry was dominated by bioMιrieux (France), Danaher (US), Becton, Dickinson and Company (US), Roche (Switzerland), and Abbott (US). Other players in this market include T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), CytoSorbents (US), and EKF (US), among others.

Stakeholders

  • Sepsis diagnostic device manufacturers
  • Clinical laboratories
  • Hospitals and clinics
  • Research institutes and clinical research organizations (CROs)
  • Sepsis diagnostic device suppliers and distributors
  • Blood culture media manufacturers
  • Blood culture media distributors and suppliers
  • Market research and consulting firms

Scope of the Report

This report categorizes the global market into the following segments and subsegments:

Global Sepsis Diagnostics Market, by Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
  • Microfluidics
  • Biomarkers

Global Sepsis Diagnostics Market, by Product

  • Blood Culture Media
  • Assays & Reagents
  • Instruments
  • Software

Global Sepsis Diagnostics Market, by Pathogen

  • Bacterial Sepsis
    • Gram-positive bacteria
    • Gram-negative bacteria
  • Fungal Sepsis
  • Other Pathogens

Global Sepsis Diagnostics Market, by Method

  • Conventional Diagnostics
  • Automated Diagnostics

Global Sepsis Diagnostics Market, by Test Type

  • Laboratory Tests
  • Point-of-care Tests

Global Sepsis Diagnostics Market, by End User

  • Hospitals
  • Pathology & Reference Laboratories

Global Sepsis Diagnostics Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)
    • Latin America
    • Middle East & Africa

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies in the market

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

The global market is projected to reach USD 613.9 Million by 2023 from USD 396.6 Million in 2018, at a CAGR of 9.1% during the forecast period. Factors such as rising prevalence of sepsis across the globe, increasing geriatric population, growing government initiatives for creating sepsis awareness, and high incidence of hospital-acquired infections are expected to drive the demand for sepsis diagnosis during the study period.

This report broadly segments the market into technology, product, pathogen, method, test type, end user, and region.

On the basis of technology, the market is segmented into microbiology, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2017, the microbiology segment accounted for the largest share of the market. This share can be attributed to the low cost of microbiology techniques and the wide use of blood culture methods for the diagnosis of sepsis.

On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment is estimated to command the largest share of the global market in 2018. The large share of this segment can be attributed to the increasing use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis.

On the basis of methods, the market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023. Accurate detection of positive blood cultures, quick turnaround time, and reduced risk of contamination is contributing to the growth of this segment.

On the basis of test type, the market is further segmented into laboratory tests and point-of-care tests. The laboratory tests segment is estimated to account for the largest share of the market in 2018. The large share of this segment can be attributed to the high use of conventional blood culture tests for sepsis diagnosis, lack of awareness about POC sepsis diagnostic tests, and low cost of laboratory testing services.

The market on the basis of pathogens is segmented into bacterial sepsis, fungal sepsis, and other infectious pathogens (viral and parasitic infection). The bacterial sepsis segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to the growing number of bacterial sepsis cases and increasing number of surgical procedures.

The sepsis diagnostics market on the basis of end user is segmented into hospitals and pathology & reference laboratories. The hospitals segment is estimated to account for the largest share of the market in 2018. The large share of this segment can be attributed to the rising number of initiatives taken by hospitals for sepsis diagnosis coupled with the prevalence of sepsis across the globe.

Sepsis Diagnostics Market, by Region, 2023

To get more details on this report, Request FREE Sample

The report covers the market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2018, due to the growing prevalence of sepsis, fast adoption of high-end sepsis diagnostics devices, and rising government support for sepsis-related research.

The major players of Sepsis Diagnostics Market are bioMιrieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 18)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
    1.4 Markets Covered
           1.4.1 Years Considered for the Study
    1.5 Currency
    1.6 Limitations
    1.7 Stakeholders

2 Research Methodology (Page No. - 21)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Key Industry Insights
           2.1.3 Market Size Estimation Methodology
           2.1.4 Bottom-Up Approach
           2.1.5 Top-Down Approach
           2.1.6 Research Design
           2.1.7 Market Data Validation and Triangulation
           2.1.8 Assumptions for the Study

3 Executive Summary (Page No. - 31)

4 Premium Insights (Page No. - 36)
    4.1 Sepsis Diagnostics: Market Overview
    4.2 Market, By Technology
    4.3 Geographic Analysis: Market, By Product and Region
    4.4 Market, By Pathogen
    4.5 Market, By Method
    4.6 Geographic Snapshot of the Market

5 Market Overview (Page No. - 40)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 High Incidence of Sepsis in the Adult Population
                    5.2.1.1 Increasing Incidence of Sepsis in Neonates
                    5.2.1.2 Growing Incidence of Hospital-Acquired Infections
                    5.2.1.3 Increasing Number of Surgical Procedures
                    5.2.1.4 Increasing Burden of Pneumonia
                    5.2.1.5 Influx of Novel Sepsis Diagnostic Products
                    5.2.1.6 Rising Initiatives to Increase the Awareness and Drive the Adoption of Sepsis Diagnostic Tests
                    5.2.1.7 Funding for Sepsis-Related Research Activities
           5.2.2 Restraints
                    5.2.2.1 Lack of Established Reimbursement Policies for Sepsis
                    5.2.2.2 High Cost of Automated Diagnostic Devices
           5.2.3 Opportunities
                    5.2.3.1 Development of Rapid Diagnostic/POC Techniques for Early Sepsis Diagnosis
                    5.2.3.2 Evolution of Novel Biomarkers for Sepsis Diagnosis
           5.2.4 Challenges
                    5.2.4.1 Lack of Standard Protocols and Awareness for Sepsis Diagnosis and Treatment
                    5.2.4.2 Shortage of Skilled Healthcare Professionals

6 Sepsis Diagnostics Market, By Technology (Page No. - 51)
    6.1 Introduction
    6.2 Microbiology
    6.3 Molecular Diagnostics
           6.3.1 Polymerase Chain Reaction
           6.3.2 Peptide Nucleic Acid-Fluorescent in Situ Hybridization
           6.3.3 Microarrays
           6.3.4 Syndromic Panel-Based Testing
    6.4 Immunoassay
    6.5 Flow Cytometry
    6.6 Microfluidics
    6.7 Biomarkers

7 Sepsis Diagnostics Market, By Product (Page No. - 60)
    7.1 Introduction
    7.2 Instruments
    7.3 Blood Culture Media
    7.4 Assays & Reagents
    7.5 Software

8 Sepsis Diagnostics Market, By Method (Page No. - 67)
    8.1 Introduction
    8.2 Conventional Diagnostics
    8.3 Automated Diagnostics

9 Sepsis Diagnostics Market, By Pathogen (Page No. - 72)
    9.1 Introduction
    9.2 Bacterial Sepsis
           9.2.1 Gram-Negative Bacterial Sepsis
           9.2.2 Gram-Positive Bacterial Sepsis
    9.3 Fungal Sepsis
    9.4 Other Pathogens

10 Sepsis Diagnostics Market, By Test Type (Page No. - 79)
     10.1 Introduction
     10.2 Laboratory Tests
     10.3 Point-Of-Care Tests

11 Sepsis Diagnostics Market, By End User (Page No. - 85)
     11.1 Introduction
     11.2 Hospitals
     11.3 Pathology & Reference Laboratories

12 Sepsis Diagnostics Market, By Region (Page No. - 89)
     12.1 Introduction
     12.2 North America
             12.2.1 US
             12.2.2 Canada
     12.3 Europe
             12.3.1 Germany
             12.3.2 France
             12.3.3 UK
             12.3.4 Rest of Europe (RoE)
     12.4 Asia Pacific
             12.4.1 Japan
             12.4.2 China
             12.4.3 India
             12.4.4 Rest of Asia Pacific
     12.5 Rest of the World
             12.5.1 Latin America
             12.5.2 Middle East & Africa

13 Competitive Landscape (Page No. - 143)
     13.1 Overview
     13.2 Market Share Analysis
     13.3 Competitive Scenario
             13.3.1 Product Launches and Approvals, 2015–2017
             13.3.2 Partnerships and Collaborations, 2015–2018
             13.3.3 Mergers and Acquisitions

14 Company Profiles (Page No. - 147)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     14.1 Biomιrieux
     14.2 T2 Biosystems
     14.3 Luminex
     14.4 Becton, Dickinson, and Company (BD)
     14.5 Roche Diagnostics (A Subsidiary of F. Hoffmann-LA Roche Ltd.)
     14.6 Danaher
     14.7 Thermo Fisher Scientific
     14.8 Bruker
     14.9 Abbott
     14.10 Immunexpress
     14.11 Response Biomedical
     14.12 Axis-Shield Diagnostics
     14.13 Cytosorbents
     14.14 Mitsubishi Chemical Europe
     14.15 EKF Diagnostics

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

15 Appendix (Page No. - 183)
     15.1 Discussion Guide
     15.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     15.3 Introducing RT: Real-Time Market Intelligence
     15.4 Available Customizations
     15.5 Related Reports
     15.6 Author Details


List of Tables (130 Tables)

Table 1 Sepsis Diagnostics Market, By Technology, 2016–2023 (USD Million)
Table 2 Microbiology Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 3 Molecular Diagnostics Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 4 Immunoassay Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 5 Flow Cytometry Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 6 Microfluidics Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 7 Biomarkers Market for Sepsis Diagnosis, By Region, 2016–2023 (USD Million)
Table 8 Market, By Product, 2016–2023 (USD Million)
Table 9 Sepsis Diagnostic Instruments Market, By Region, 2016–2023 (USD Million)
Table 10 Sepsis Diagnostic Blood Culture Media Market, By Region, 2016–2023 (USD Million)
Table 11 Sepsis Diagnostic Assays & Reagents Market, By Region, 2016–2023 (USD Million)
Table 12 Sepsis Diagnostic Software Market, By Region, 2016–2023 (USD Million)
Table 13 Market, By Method, 2016–2023 (USD Million)
Table 14 Conventional Diagnostics Market, By Region, 2016–2023 (USD Million)
Table 15 Automated Diagnostics Market, By Region, 2016–2023 (USD Million)
Table 16 Market, By Pathogen, 2016–2023 (USD Million)
Table 17 Bacterial Sepsis Market, By Type, 2016–2023 (USD Million)
Table 18 Bacterial Sepsis Market, By Region, 2016–2023 (USD Million)
Table 19 Bacterial Causes of Adult Sepsis
Table 20 Bacterial Causes of Adult Sepsis
Table 21 Fungal Sepsis Market, By Region, 2016–2023 (USD Million)
Table 22 Other Pathogens Market, By Region, 2016–2023 (USD Million)
Table 23 Market, By Test Type, 2016–2023 (USD Million)
Table 24 Laboratory Pointers of Sepsis
Table 25 Laboratory Tests Market, By Region, 2016–2023 (USD Million)
Table 26 Point-Of-Care Tests Market, By Region, 2016-2023 (USD Million)
Table 27 Market, By End User, 2016–2023 (USD Million)
Table 28 Market for Hospitals, By Region, 2016–2023 (USD Million)
Table 29 Market for Pathology & Reference Laboratories, By Region, 2016–2023 (USD Million)
Table 30 Market, By Region, 2016–2023 (USD Million)
Table 31 North America: Market, By Country, 2016–2023 (USD Million)
Table 32 North America: Market, By Technology, 2016–2023 (USD Million)
Table 33 North America: Market, By Product, 2016–2023 (USD Million)
Table 34 North America: Market, By Pathogen, 2016–2023 (USD Million)
Table 35 North America: Market, By Method, 2016–2023 (USD Million)
Table 36 North America: Market, By Test Type, 2016–2023 (USD Million)
Table 37 North America: Market, By End User, 2016–2023 (USD Million)
Table 38 US: Market, By Technology, 2016–2023 (USD Million)
Table 39 US: Sepsis Diagnostics Market, By Product, 2016–2023 (USD Million)
Table 40 US: Market, By Pathogen, 2016–2023 (USD Million)
Table 41 US: Market, By Method, 2016–2023 (USD Million)
Table 42 US: Market, By Test Type, 2016–2023 (USD Million)
Table 43 US: Market, By End User, 2016–2023 (USD Million)
Table 44 Canada: Market, By Technology, 2016–2023 (USD Million)
Table 45 Canada: Market, By Product, 2016–2023 (USD Million)
Table 46 Canada: Market, By Pathogen, 2016–2023 (USD Million)
Table 47 Canada: Market, By Method, 2016–2023 (USD Million)
Table 48 Canada: Market, By Test Type, 2016–2023 (USD Million)
Table 49 Canada: Market, By End User, 2016–2023 (USD Million)
Table 50 Europe: Market, By Country, 2016–2023 (USD Million)
Table 51 Europe: Market, By Technology, 2016–2023 (USD Million)
Table 52 Europe: Market, By Product, 2016–2023 (USD Million)
Table 53 Europe: Market, By Pathogen, 2016–2023 (USD Million)
Table 54 Europe: Market, By Method, 2016–2023 (USD Million)
Table 55 Europe: Market, By Test Type, 2016–2023 (USD Million)
Table 56 Europe: Market, By End User, 2016–2023 (USD Million)
Table 57 Germany: Market, By Technology, 2016–2023 (USD Million)
Table 58 Germany: Market, By Product, 2016–2023 (USD Million)
Table 59 Germany: Sepsis Market, By Pathogen, 2016–2023 (USD Million)
Table 60 Germany: Market, By Method, 2016–2023 (USD Million)
Table 61 Germany: Market, By Test Type, 2016–2023 (USD Million)
Table 62 Germany: Market, By End User, 2016–2023 (USD Million)
Table 63 France: Market, By Technology, 2016–2023 (USD Million)
Table 64 France: Market, By Product, 2016–2023 (USD Million)
Table 65 France: Market, By Pathogen, 2016–2023 (USD Million)
Table 66 France: Market, By Method, 2016–2023 (USD Million)
Table 67 France: Market, By Test Type, 2016–2023 (USD Million)
Table 68 France: Market, By End User, 2016–2023 (USD Million)
Table 69 UK: Market, By Technology, 2016–2023 (USD Million)
Table 70 UK: Market, By Product, 2016–2023 (USD Million)
Table 71 UK: Market, By Pathogen, 2016–2023 (USD Million)
Table 72 UK: Market, By Method, 2016–2023 (USD Million)
Table 73 UK: Market, By Test Type, 2016–2023 (USD Million)
Table 74 UK: Market, By End User, 2016–2023 (USD Million)
Table 75 RoE: Market, By Technology, 2016–2023 (USD Million)
Table 76 RoE: Market, By Product, 2016–2023 (USD Million)
Table 77 RoE: Market, By Pathogen, 2016–2023 (USD Million)
Table 78 RoE: Market, By Method, 2016–2023 (USD Million)
Table 79 RoE: Market, By Test Type, 2016–2023 (USD Million)
Table 80 RoE: Market, By End User, 2016–2023 (USD Million)
Table 81 APAC: Market, By Country, 2016–2023 (USD Million)
Table 82 APAC: Market, By Technology, 2016–2023 (USD Million)
Table 83 APAC: Market, By Product, 2016–2023 (USD Million)
Table 84 APAC: Market, By Pathogen, 2016–2023 (USD Million)
Table 85 APAC: Market, By Method, 2016–2023 (USD Million)
Table 86 APAC: Market, By Test Type, 2016–2023 (USD Million)
Table 87 APAC: Market, By End User, 2016–2023 (USD Million)
Table 88 Japan: Market, By Technology, 2016–2023 (USD Million)
Table 89 Japan: Market, By Product, 2016–2023 (USD Million)
Table 90 Japan: Market, By Pathogen, 2016–2023 (USD Million)
Table 91 Japan: Market, By Method, 2016–2023 (USD Million)
Table 92 Japan: Sepsis Diagnostics Market, By Test Type, 2016–2023 (USD Million)
Table 93 Japan: Market, By End User, 2016–2023 (USD Million)
Table 94 China: Market, By Technology, 2016–2023 (USD Million)
Table 95 China: Market, By Product, 2016–2023 (USD Million)
Table 96 China: Market, By Pathogen, 2016–2023 (USD Million)
Table 97 China: Market, By Method, 2016–2023 (USD Million)
Table 98 China: Market, By Test Type, 2016–2023 (USD Million)
Table 99 China: Market, By End User, 2016–2023 (USD Million)
Table 100 India: Market, By Technology, 2016–2023 (USD Million)
Table 101 India: Market, By Product, 2016–2023 (USD Million)
Table 102 India: Sepsis Diagnostics Market, By Pathogen, 2016–2023 (USD Million)
Table 103 India: Market, By Method, 2016–2023 (USD Million)
Table 104 India: Market, By Test Type, 2016–2023 (USD Million)
Table 105 India: Market, By End User, 2016–2023 (USD Million)
Table 106 RoAPAC: Market, By Technology, 2016–2023 (USD Million)
Table 107 RoAPAC: Market, By Product, 2016–2023 (USD Million)
Table 108 RoAPAC: Market, By Pathogen, 2016–2023 (USD Million)
Table 109 RoAPAC: Sepsis Diagnostics Market, By Method, 2016–2023 (USD Million)
Table 110 RoAPAC: Market, By Test Type, 2016–2023 (USD Million)
Table 111 RoAPAC: Market, By End User, 2016–2023 (USD Million)
Table 112 RoW: Market, By Region, 2016–2023 (USD Million)
Table 113 RoW: Market, By Technology, 2016–2023 (USD Million)
Table 114 RoW: Market, By Product, 2016–2023 (USD Million)
Table 115 RoW: Market, By Pathogen, 2016–2023 (USD Million)
Table 116 RoW: Market, By Method, 2016–2023 (USD Million)
Table 117 RoW: Market, By Test Type, 2016–2023 (USD Million)
Table 118 RoW: Market, By End User, 2016–2023 (USD Million)
Table 119 Latin America: Market, By Technology, 2016–2023 (USD Million)
Table 120 Latin America: Sepsis Diagnostic Market, By Product, 2016–2023 (USD Million)
Table 121 Latin America: Market, By Pathogen, 2016–2023 (USD Million)
Table 122 Latin America: Market, By Method, 2016–2023 (USD Million)
Table 123 Latin America: Market, By Test Type, 2016–2023 (USD Million)
Table 124 Latin America: Market, By End User, 2016–2023 (USD Million)
Table 125 Middle East & Africa: Market, By Technology, 2016–2023 (USD Million)
Table 126 Middle East & Africa: Market, By Product, 2016–2023 (USD Million)
Table 127 Middle East & Africa: Market, By Pathogen, 2016–2023 (USD Million)
Table 128 Middle East & Africa: Sepsis Diagnostics Market, By Method, 2016–2023 (USD Million)
Table 129 Middle East & Africa: Market, By Test Type, 2016–2023 (USD Million)
Table 130 Middle East & Africa: Market, By End User, 2016–2023 (USD Million)


List of Figures (41 Figures)

Figure 1 Global Sepsis Diagnostics Market: Research Methodology Steps
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Data Triangulation Methodology
Figure 4 Global Sepsis Diagnostic Market, By Product, 2018
Figure 5 Global Market, By Technology, 2023
Figure 6 Global Market, By Method, 2018
Figure 7 Global Market, By Test Type, 2018 vs 2023
Figure 8 Global Market, By Pathogen, 2018
Figure 9 Global Market, By End User, 2018
Figure 10 Global Market, By Region, 2018 (USD Million)
Figure 11 Rising Prevalence of Sepsis is Driving the Growth of Sepsis Diagnostics Market Across the Globe
Figure 12 Microbiology Segment Will Continue to Dominate the Market in 2023
Figure 13 Blood Culture Media Segment to Dominate the Global Sepsis Diagnostics Products Market in 2018
Figure 14 Bacterial Sepsis Segment to Dominate the Market During the Forecast Period
Figure 15 Conventional Diagnostics Method to Dominate the Market During the Forecast Period
Figure 16 Asia Pacific to Register the Highest CAGR During the Forecast Period
Figure 17 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Biomarkers Segment to Witness the Highest Growth During the Forecast Period
Figure 19 Blood Culture Media Segment to Witness Highest Growth During the Forecast Period
Figure 20 Conventional Diagnostics Segment to Dominate the Market in 2023
Figure 21 Bacterial Sepsis Segment to Register the Highest Growth Rate During the Forecast Period
Figure 22 Point-Of-Care Tests Segment to Grow at the Highest CAGR
Figure 23 Hospitals Segment to Dominate the Sepsis Diagnostics Market in 2023
Figure 24 Sepsis Incidence, By Country, 2017
Figure 25 Market: Growth Forecast, By Region (2018–2023)
Figure 26 North America: Market Snapshot
Figure 27 Europe: Market Snapshot
Figure 28 APAC: Market Snapshot
Figure 29 Key Developments By Leading Market Players in the Market, 2015–2017
Figure 30 Market Share, By Key Players, 2016
Figure 31 Biomιrieux: Company Snapshot
Figure 32 T2 Biosystems: Company Snapshot
Figure 33 Luminex: Company Snapshot
Figure 34 BD: Company Snapshot
Figure 35 Roche Diagnostics: Company Snapshot
Figure 36 Danaher: Company Snapshot
Figure 37 Thermo Fisher Scientific: Company Snapshot
Figure 38 Bruker: Company Snapshot
Figure 39 Abbott: Company Snapshot
Figure 40 Cytosorbents: Company Snapshot
Figure 41 EKF Diagnostics: Company Snapshot

To get more details on this report, Request FREE Sample


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 4575
Published ON
Oct, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home